MedX Health Corp., a speculative micro-cap stock with a current equity valuation of just $12 million, has developed its SIAscopeTM, a Class 2 medical scanning device which, used in conjunction with an HD camera, can scan suspicious – potentially cancerous – moles and lesions and penetrate two millimeters (mm) below the surface of the skin to accurately generate high quality images. See Figure 1 and 2. These images are then uploaded to MedX’s proprietary DermSecureTM telemedicine platform to be securely transmitted to dermatologists for assessment…
Stephen, who became a major investor in the company in recent months, and who joined the Board in April, 2023, brings extensive knowledge and years of financial management and entrepreneurial experience, and was instrumental in the introduction of the project with PharmaChoice which has just been launched in Canada,” said Ken McKay, Chairman of the MedX Board of Directors….
MedX Health Corp. (“MedX” or the “Company“) (TSXV: MDX), a global leader in teledermatology, is pleased to announce a Memorandum of Understanding for the launch of a new commercialization pilot project (the “Pilot Project”) with PharmaChoice Canada (“PharmaChoice”), one of Canada’s fastest‐growing pharmacy groups
If you need more information about our services or our business vision please reach out and we will connect you with the proper member of our team who can serve you best!